-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Product Theaters

Saturday, December 9, 2023

Saturday | Sunday | Monday | top

11:30 AM-12:30 PM

A Proven CAR T Cell Therapy With Extensive Real-World Experience For RRMM
Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types
The FIRST and ONLY Therapy Approved for Adults with Indolent Systemic Mastocystosis (ISM)

Sunday, December 10, 2023

Saturday | Sunday | Monday | top

8:00 AM-9:00 AM

APHEXDA (motixafortide): Learn about this new FDA approved treatment option
A Treatment Option for Relapsed or Refractory Multiple Myeloma from Pfizer
Could there be a Link Between Autoimmune Cytopenias, Lymphadenopathy, and Splenomegaly? A Physician''s Perspective and a Patient''s Experience
Exploring Time Off Treatment with a BCL-2 Inhibitor
Unveiling a Subcutaneous Therapy for 3L+ DLBCL

11:30 AM-12:30 PM

A Complement Inhibitor for PNH
A Discussion on a Treatment Option for Sickle Cell Disease
Janssen invites you to learn about a treatment for adult patients with RRMM who have received at least four prior lines of therapy, including a PI, IMiD, and anti-CD38 monoclonal antibody
Learn about an alternative treatment for certain B-cell malignancies. This program is sponsored by Lilly USA, LLC.
Learn more about a new FDA-approved treatment, OJJAARA (momelotinib)
Long-term Clinical Trial Results for a BTKi in the Treatment of CLL/SLL
Treatment Options in Relapsed Refractory Multiple Myeloma: Clinical Data and Patient Cases

Monday, December 11, 2023

Saturday | Sunday | Monday | top

8:00 AM-9:00 AM

Achieving Higher Factor VIII Levels in Hemophilia A
An Advancement in Frontline DLBCL and A Fixed-Duration Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma
A new, first-in-class treatment for RRMM patients
Hear from Novartis about a new treatment for adults with PNH
Latest Advancement in Allogeneic Hematopoietic Cell Transplantation

12:15 PM-1:15 PM

An FDA approved treatment option for anemia in LR-MDS
CARVYKTI Product Summary for Healthcare Providers
Outcomes and Economic Impact of Treatment with CABLIVI (caplacizumab-yhdp)